Interleukin-6 Mediates Resistance to PI3K-pathway–targeted Therapy in Lymphoma

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-6057-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC